All relevant data are within the paper.

Introduction {#sec001}
============

*Campylobacter jejuni* is among the leading causes of bacterial diarrheal disease worldwide. In the U.S., *Campylobacter* is currently the second cause of foodborne bacterial disease behind Salmonella with an estimated incidence of 14.22 cases per 100,000 million annually, affecting all age classes \[[@pone.0144349.ref001]\]. In developing countries, the incidence is higher and predominantly affects children less than two years old \[[@pone.0144349.ref002], [@pone.0144349.ref003]\]. It is estimated that 5.5 to 18% of children under the age of 5 years develop diarrhea caused by this pathogen \[[@pone.0144349.ref004]\]. In addition, *C*. *jejuni* is associated with several sequelae, including irritable bowel syndrome (IBS) \[[@pone.0144349.ref005], [@pone.0144349.ref006]\], reactive arthritis \[[@pone.0144349.ref007]\], and Guillain-Barré syndrome \[[@pone.0144349.ref008]\]. Moreover, recent studies suggest the association of repeated *C*. *jejuni* infections with malnutrition and stunting \[[@pone.0144349.ref009]\].

A decade of research utilizing whole genome sequencing and Comparative Genomic Hybridization (CGH) using whole genome microarray analyses has revealed extensive genetic variability among *C*. *jejuni* strains \[[@pone.0144349.ref010]--[@pone.0144349.ref019]\]. The most variable genetic loci are those involved in the synthesis and modification of bacterial surface carbohydrate structures including the genes involved in flagellar O-linked glycosylation, genes involved in biosynthesis of lipooligosachharide (LOS), and the polysaccharide capsule (CPS) \[[@pone.0144349.ref010]\], all of which contribute to virulence in a variety of ways. Non-encapsulated mutants are defective in colonization of chickens and mice \[[@pone.0144349.ref020], [@pone.0144349.ref021]\], and show reduced virulence in infant ferret \[[@pone.0144349.ref022]\]. Moreover, the CPS is required for resistance to complement-mediated killing \[[@pone.0144349.ref021]--[@pone.0144349.ref024]\]. CPS is also the primary determinant of the Penner or heat-stable serotyping scheme, of which there are 47 *C*. *jejuni* serotypes \[[@pone.0144349.ref025], [@pone.0144349.ref026]\], some of which fall into complexes of related serotypes ([Fig 1](#pone.0144349.g001){ref-type="fig"}) \[[@pone.0144349.ref025], [@pone.0144349.ref027], [@pone.0144349.ref028]\]. *C*. *jejuni* CPSs are exported via a highly conserved ABC-transporter mechanism similar to class 2 and class 3 capsules of *E*. *coli* \[[@pone.0144349.ref029]\]. The variable genes that encode the enzymes responsible for synthesis of the serotype-specific CPS are located between two blocks of ABC transporter genes (*kpsMTEDF* at one end of the locus, and *kpsCS* at the other end. To date the sequence of 18 of these variable CPS loci have been published \[[@pone.0144349.ref010], [@pone.0144349.ref015], [@pone.0144349.ref019], [@pone.0144349.ref030]--[@pone.0144349.ref032]\], and the remainder are in preparation (C. T Parker, unpublished; F. Poly, unpublished). We are currently evaluating a polysaccharide CPS conjugate approach against *C*. *jejuni* -mediated disease \[[@pone.0144349.ref029], [@pone.0144349.ref033], [@pone.0144349.ref034]\]. A final vaccine formulation, like most other polysaccharide conjugate vaccines would be multivalent \[[@pone.0144349.ref035]\]. The criteria for inclusion of specific CPS types into a multivalent formulation would be based on both incidence of specific CPS types and any association of specific CPS types with severity of illness. However, a recent systematic review of published studies on Penner serotyping of strains isolated from 1978--2002 demonstrated a paucity of data from developing countries, where a vaccine is the most needed \[[@pone.0144349.ref027]\]. Additional information on CPS types present in endemic areas is clearly needed to facilitate development of a multivalent conjugate vaccine approach. Unfortunately, the complexity and costs of Penner serotyping have limited its use in recent years. To circumvent this problem, a partial multiplex PCR methodology was successfully introduced in order to gain more information on *C*. *jejuni* CPS distribution worldwide \[[@pone.0144349.ref032]\]. The initial methodology was able to distinguished 17 of the more frequently isolated CPS types. In this report we present an updated version of the multiplex PCR that is now able to identify all known CPS *C*. *jejuni* types. These data indicate that the 47 serotypes can be collapsed into 35 CPS types ([Fig 1](#pone.0144349.g001){ref-type="fig"}). Here, we also describe application of this method to a collection of 996 *C*. *jejuni* clinical isolates collected from South and Southeast Asia from 1998 to 2010.

![This cartoon summarizes the Penner types association into complexes commonly found in literature.\
The variable CPS biosynthesis loci of type strains belonging to the same complex present a high degree of homology \[[@pone.0144349.ref031], [@pone.0144349.ref032]\].](pone.0144349.g001){#pone.0144349.g001}

Materials and Methods {#sec002}
=====================

DNA purification {#sec003}
----------------

Frozen stocks of *C*. *jejuni* were subcultured on Brucella agar plates with 5% sheep blood (BAP) and incubated at 37°C under microaerobic conditions (5% O~2~, 10% CO~2~, 85% N~2~). Genomic DNA extractions of *C*. *jejuni* isolates were performed using DNeasy tissue extraction kits (Qiagen, USA) following the manufacturer's instructions. Genomic DNAs were routinely stored at -20°C.

Whole genome sequencing and CPS loci annotation {#sec004}
-----------------------------------------------

CPS loci sequences were extracted from the USDA-ARS CRIS 5325-42000-047 project aimed at the whole genome sequencing of 45 *C*. *jejuni* Penner type strains. Strains are shown in [Table 1](#pone.0144349.t001){ref-type="table"}. Whole-genome sequencing of the 45 *C*. *jejuni* Penner type strains to a depth of \~20x was performed using shotgun and paired-end (8 to 12 kb) libraries and was generated on a Roche 454 FLX+ sequencing system with Titanium chemistry. The Roche Newbler assembler (version 2.3) was used to assemble reads into contigs. Genome closing utilized a combination of steps. The contigs were aligned to other *C*. *jejuni* genomes. Scaffold gaps were filled by a combination of referenced assemblies of approximately one million Illumina MiSeq reads/strain to the Newbler contigs using Geneious software (Biomatters, New Zealand) and the identification of repeated contigs using the Perlscript contig_extender2. Certain gaps were validated using PCR amplification and Sanger sequencing. All base calls were validated using the Illumina MiSeq reads, which provided an additional 100× coverage. Shotgun library preparations and sequence procedures were performed according to established procedures and manufacturer's instructions. Annotation of the variable region of CPS biosynthesis, between *kpsC* and *kpsF* ([Fig 2](#pone.0144349.g002){ref-type="fig"}), was made using Artemis software (Sanger institute).

10.1371/journal.pone.0144349.t001

###### Bacterial strains used for analysis and validation of the capsule multiplex PCR.

![](pone.0144349.t001){#pone.0144349.t001g}

  Strain       Penner type   Reference
  ------------ ------------- ----------------------------
  ATCC 43429   HS1           \[[@pone.0144349.ref036]\]
  NCTC 11168   HS2           \[[@pone.0144349.ref010]\]
  ATCC 43431   HS3           \[[@pone.0144349.ref036]\]
  ATCC 43432   HS4           \[[@pone.0144349.ref036]\]
  GC8486       HS4/13/64     \[[@pone.0144349.ref014]\]
  ATCC 43433   HS5           \[[@pone.0144349.ref036]\]
  81116        HS6           \[[@pone.0144349.ref037]\]
  ATCC 43435   HS7           \[[@pone.0144349.ref036]\]
  ATCC 43436   HS8           \[[@pone.0144349.ref036]\]
  ATCC 43437   HS9           \[[@pone.0144349.ref036]\]
  ATCC 43438   HS10          \[[@pone.0144349.ref036]\]
  RM3415       HS11          \[[@pone.0144349.ref038]\]
  RM3204       HS12          \[[@pone.0144349.ref038]\]
  ATCC 43441   HS13          \[[@pone.0144349.ref036]\]
  ATCC 43442   HS15          \[[@pone.0144349.ref036]\]
  RM3417       HS16          \[[@pone.0144349.ref038]\]
  ATCC 43444   HS17          \[[@pone.0144349.ref036]\]
  RM3419       HS18          \[[@pone.0144349.ref038]\]
  ATCC 43446   HS19          \[[@pone.0144349.ref036]\]
  ATCC 43447   HS21          \[[@pone.0144349.ref036]\]
  ATCC 43448   HS22          \[[@pone.0144349.ref036]\]
  81--176      HS23/36       \[[@pone.0144349.ref039]\]
  RM3423       HS27          \[[@pone.0144349.ref038]\]
  RM3424       HS29          \[[@pone.0144349.ref038]\]
  ATCC 43452   HS31          \[[@pone.0144349.ref036]\]
  RM3425       HS32          \[[@pone.0144349.ref038]\]
  ATCC 43454   HS33          \[[@pone.0144349.ref036]\]
  RM3426       HS35          \[[@pone.0144349.ref038]\]
  RM3428       HS37          \[[@pone.0144349.ref038]\]
  RM3429       HS38          \[[@pone.0144349.ref038]\]
  ATCC 43459   HS40          \[[@pone.0144349.ref036]\]
  ATCC 43460   HS41          \[[@pone.0144349.ref036]\]
  ATCC 43461   HS42          \[[@pone.0144349.ref036]\]
  ATCC 43463   HS44          \[[@pone.0144349.ref036]\]
  RM3432       HS45          \[[@pone.0144349.ref038]\]
  ATCC 43465   HS50          \[[@pone.0144349.ref036]\]
  RM3434       HS52          \[[@pone.0144349.ref038]\]
  RM1221       HS53          \[[@pone.0144349.ref040]\]
  ATCC 43469   HS55          \[[@pone.0144349.ref036]\]
  RM3436       HS57          \[[@pone.0144349.ref038]\]
  ATCC 43470   HS58          \[[@pone.0144349.ref036]\]
  RM3438       HS60          \[[@pone.0144349.ref038]\]
  RM3439       HS62          \[[@pone.0144349.ref038]\]
  RM3440       HS63          \[[@pone.0144349.ref038]\]
  ATCC 49302   HS64          \[[@pone.0144349.ref036]\]
  RM3442       HS65          \[[@pone.0144349.ref038]\]

![Illustration of the *C*. *jejui* CPS loci described in this study.\
Putative gene functions were assigned via homology to a protein database by BLAST analyses.](pone.0144349.g002){#pone.0144349.g002}

PCR primer design {#sec005}
-----------------

Selection of CPS regions for primer design was performed as previously described \[[@pone.0144349.ref031], [@pone.0144349.ref032]\]. Briefly, specific CPS sequences (variable capsule region between *kpsC* and *kpsF*) for a particular serotype were isolated by performing a local stand alone BLAST using a database encompassing the nucleotides sequences of all 47 available *C*. *jejuni* capsule loci (C. T. Parker, unpublished). The selected nucleotide regions were used for multiplex primer design. The sites where the primers were designed are displayed in [Fig 2](#pone.0144349.g002){ref-type="fig"}. Multiplex primers were designed via the online software Primer3 \[[@pone.0144349.ref041]\] using the following parameters: length between 18 and 30 residues, 20 to 50% GC, T~m~ ranging from 57 to 63°C. Primer sets to be included in the original or new multiplex mixes were designed in order to amplify a PCR of least 20 base pairs smaller/larger than the other amplicons of the same mix. Following design, primers were compared to *C*. *jejuni* genomes via NCBI BLAST software to exclude potential amplification outside the CPS locus.

Multiplex PCR parameters {#sec006}
------------------------

PCRs were performed using 0.4 μM of each primers of their respective mixes in 25-μl reactions containing 1--10 ng DNA template, 1× PCR Gold Buffer, 2.0 mM MgCl~2~, 0.3 mM each dNTP and 1.25 U of AmpliTaq Gold DNA Polymerase (Life Technologies, USA) using Dyad thermal cycler (Bio-Rad, USA). DNA amplification was performed using an initial denaturation step at 94°C for 5 min; followed by 30 cycles of amplification (denaturation at 94°C for 1 min, annealing at 52°C for 1 min, and extension at 72°C for 1 min and ending with a final extension at 72°C for 10 min. At the end of the reaction, the PCR amplicons were analyzed by gel electrophoresis on 10-cm-long 2% agarose gels in 0.5× TBE (Tris-borate-EDTA) buffer at 175 V for 75 min. The serotypes were determined by the size of the PCR amplicons by comparison with a 100-bp molecular size standard (New England BioLabs, USA).

Validation of PCR primers and multiplex mixes {#sec007}
---------------------------------------------

Primer sets were validated individually on their respective DNA type, and, if an amplicon of the predicted size was observed, the primer set was included in its multiplex mix. The newly generated multiplex mix was then used in a PCR reaction on a collection of 47 *C*. *jejuni* DNA ([Table 1](#pone.0144349.t001){ref-type="table"}). The newly designed primer pair was selected and incorporated in multiplex mixes only if it yielded the right size amplicon during PCR performed on its target or related DNA CPS type (i.e. a strain that was part of the same complex) and if no false amplification was observed on the remaining CPS types tested. The newly formulated multiplex mix was finally tested against the DNA of 47 CPS types individually and deemed worthy only if the expected right size amplicons were obtained and no false positives were observed. There are four exceptions to this rule, as discussed below.

Clinical *C*. *jejuni* isolates {#sec008}
-------------------------------

A total of 996 archived *C*. *jejuni* isolates were included in this study. These isolates were from twelve studies on etiology of diarrhea among travelers, military personnel and indigenous population from Southeast Asia during 1998--2010 as shown in [Table 2](#pone.0144349.t002){ref-type="table"}. All stool samples were routinely cultured for enteric bacteria pathogens at the Armed Forces Research Institute of Medical Sciences (AFRIMS). The Cobra Gold exercises in 1998--2003 were approved by ethical review committees from Walter Reed Army Institute of Research (WRAIR) IRB. The travelers' diarrhea and diarrhea surveillance studies in Thailand, Cambodia and Nepal were approved by ethical review committees from WRAIR IRB as well as host nation IRB (Thailand, Cambodia and Nepal). The studies involve using de-identify archived frozen *C*. *jejuni* isolated from stool samples with appropriate consent for samples donation in the future use and currently stored at the Department of Enteric Diseases, AFRIMS without any identifiable information. The studies were closed. Specimens are labeled by subject numbers and date of collection without any personal identifiers. A link to subject name, number, and personal identifier was destroyed. Data to be included in the analysis portion of this study will be demographic (age and gender), clinical (associated symptoms), and laboratory (results) data and will not include any confidential or sensitive data.

10.1371/journal.pone.0144349.t002

###### Clinical strains used to test the multiplex PCR technique.

![](pone.0144349.t002){#pone.0144349.t002g}

  Study                             Population                         Cases                        Location                           Country    Number of *C*. *jejuni*   Reference
  --------------------------------- ---------------------------------- ---------------------------- ---------------------------------- ---------- ------------------------- ----------------------------
  Cobra Gold Exercise 1998          Military personnel                 Adults                       Kanjanaburi, Utapao                Thailand   20                        \[[@pone.0144349.ref043]\]
  Cobra Gold Exercise 1999          Military personnel                 Adults                       Korat                              Thailand   83                        \[[@pone.0144349.ref043]\]
  Cobra Gold Exercise 2000          Military personnel                 Adults                       Nakornsrithammarat, Tungsong       Thailand   68                        \[[@pone.0144349.ref043]\]
  Cobra Gold Exercise 2001          Military personnel                 Adults                       Pitsanulok                         Thailand   54                        \[[@pone.0144349.ref043]\]
  Cobra Gold Exercise 2002          Military personnel                 Adults                       Sakaew                             Thailand   15                        \[[@pone.0144349.ref043]\]
  Cobra Gold Exercise 2003          Military personnel                 Adults                       Pranburi                           Thailand   23                        \[[@pone.0144349.ref043]\]
  Travelers\' diarrhea 2001--02     Travelers, indigenous population   Adults                       Bumrungrad International Hosp.     Thailand   51                        \[[@pone.0144349.ref043]\]
  Diarrheal surveillance 2004--06   Indigenous Population              Children ≤ 5 Years           Regional Hosp.                     Thailand   213                       \-
  Diarrheal surveillance 2008--10   Indigenous Population              Children ≤ 5 Years           Regional Hosp.                     Thailand   302                       \-
  Travelers\' diarrhea 2001--03     Travelers                          Adults                       CIWEC Clinic                       Nepal      46                        \-
  Diarrheal surveillance 2006--09   Indigenous Population              Children ≤ 5 Years, Adults   Bharatphur, Sukaraj, Kanti, Teku   Nepal      96                        \-
  Diarrheal surveillance 2004--06   Indigenous Population              Children ≤ 5 Years           National Pedriatric Hosp.          Cambodia   25                        \-

Cary Blair medium were used as transportation medium in these study sites. For *C*. *jejuni* culture and isolation, fresh stool or stool in Carry Blair medium was processed by a modified filtration method \[[@pone.0144349.ref042]\]. After filtration, the millipore membranes were incubated on BAP at 37°C under microaerobic conditions. The suspected colonies of *C*. *jejuni* were identified by catalase test, nitrate tests and hippurate hydrolysis. Confirmed *C*. *jejuni* isolates were kept frozen at -70°C in 15% glycerol medium.

Statistical analyses {#sec009}
--------------------

Statistical analyses presented in this manuscript were calculated using a Chi-square test.

Results and Discussion {#sec010}
======================

Description of primers and multiplex mixes {#sec011}
------------------------------------------

The previous *C*. *jejuni* CPS multiplex version was composed of two mixes, alpha and beta, that contained eight and six primer sets, respectively \[[@pone.0144349.ref032]\]. A total of 23 new primer sets were added for a total of four mixes, alpha, beta, gamma and delta. The alpha mix of the second version contains three additional primers sets (HS19, HS33 and HS63) compared to the initial published version, for a total of 11 primers sets. The beta mix was revised by moving the HS44 primer set to mix gamma and adding five new primer sets (HS5, HS12, HS21, HS27 and HS57). A positive control primer set for *C*. *jejuni* sp. was included in mix gamma following observations that other non-*jejuni Campylobacter* spp. were cross reacting with the multiplex PCR scheme (data not shown). This *C*. *jejuni*-specific primer set amplifies a 331bp region of the *lpxA* gene (involved in lipid A biosynthesis) \[[@pone.0144349.ref044]\]. Thus, results should be interpreted only if a positive amplification of a 331 bp amplicon is observed in mix gamma. Finally, mix delta contains an additional eight primer mixes. Primers and their respective PCR product sizes are listed in [Table 3](#pone.0144349.t003){ref-type="table"} and illustrated in [Fig 3](#pone.0144349.g003){ref-type="fig"}. All primer sets were tested as described in Materials and Methods.

10.1371/journal.pone.0144349.t003

###### Summary of the primer sequences included in the *C*. *jejuni* capsule multiplex typing scheme.

![](pone.0144349.t003){#pone.0144349.t003g}

  Primers           Product size (bp)   Penner Recognized                            Forward sequence                Reverse sequence                  Accession number[^a^](#t003fn001){ref-type="table-fn"}
  ----------------- ------------------- -------------------------------------------- ------------------------------- --------------------------------- --------------------------------------------------------
  ***Mix Alpha***                                                                                                                                      
  Mu_HS2            62                  HS2                                          `CAGCATTGGAGGATTTACAATATAT`     `CATCCTAGCACAACTCACTTCA`          AL111168.1[^b^](#t003fn002){ref-type="table-fn"}
  Mu_HS3            149                 HS3                                          `GGTAAGGTTGATTCTGGGTTTAAT`      `AGATTAGGCCAAGCAATGATAA`          HQ343268[^c^](#t003fn003){ref-type="table-fn"}
  Mu_HS4A           370                 HS4A[^d^](#t003fn004){ref-type="table-fn"}   `TATATTTGGTTAGGGATCCA`          `CCTAACATATCATACACTACGGT`         HQ343269[^c^](#t003fn003){ref-type="table-fn"}
  Mu_HS6            185                 HS6 & HS7                                    `CATACATTTGCTTTCAGATTCTTTAC`    `ACACGCCTATTGTTGTTGTTC`           NC_009839[^e^](#t003fn005){ref-type="table-fn"}
  Mu_HS10           229                 HS10                                         `TCTTATGCAGCACGCTGAT`           `CAAATTCAATCGACTAGCCACT`          HQ343271[^c^](#t003fn003){ref-type="table-fn"}
  Mu_HS15           325                 HS15, HS31 & HS58                            `ACAGGTAATAAAATGTGCGAGTTT`      `ATGCATCTGCAACATCATCC`            HQ343272[^c^](#t003fn003){ref-type="table-fn"}
  Mu_HS41           279                 HS41                                         `CTTACATATGCTGGTAGAGATGATATG`   `TGCAATCTCTAAAGCCCAAG`            BX545857[^f^](#t003fn006){ref-type="table-fn"}
  Mu_HS53           251                 HS53                                         `AGGCAAGCAGGAATTGTTT`           `TTAATTGCTCTTTGGCAATCTT`          CP000025.1[^g^](#t003fn007){ref-type="table-fn"}
  Mu_HS19           450                 HS19                                         `CGAGGATGAAAATGCCTCAA`          `GGCAACAAACAAACATATTCAGA`         BX545860[^f^](#t003fn006){ref-type="table-fn"}
  Mu_HS63           522                 HS63                                         `AAATTTGTTTTTCATATTTTTACGG`     `TTAGGTGCGGTTACCAAAGG`            KT893438[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS33           819                 HS33 & HS35                                  `GTAGCGGATCAGCAGCATTA`          `CATCAAAATCATCTTTTAACACCAA`       KT893436[^h^](#t003fn008){ref-type="table-fn"}
  ***Mix Beta***                                                                                                                                       
  Mu_HS1            610                 HS1                                          `TTGGCGGTAAGTTTTTGAAGA`         `GCAAGAGAAACATCTCGCCTA`           BX545859[^f^](#t003fn006){ref-type="table-fn"}
  Mu_HS4B           652                 HS4B[^i^](#t003fn009){ref-type="table-fn"}   `GTGGACATGGAACTGGGACT`          `AAAACGTTTAAAGTCAGTGGAAA`         AASY01000000[^j^](#t003fn010){ref-type="table-fn"}
  Mu_HS8            342                 HS8 & HS17                                   `TTCACGTGGAGGATTATTGG`          `TTGAACATTTCATGTGTATTCCCTA`       HQ343270[^c^](#t003fn003){ref-type="table-fn"}
  Mu_HS23/36        161                 HS23 & HS36                                  `GCTTGGGAGATGAATTTACCTTTA`      `GCTTTATATCTATCCAGTCCATTATCA`     BX545858[^f^](#t003fn006){ref-type="table-fn"}
  Mu_HS42           440                 HS42                                         `ATGGTAAAACCGGCATTTCA`          `ATGCTTCAGTTCCACCCAAA`            HQ343274[^c^](#t003fn003){ref-type="table-fn"}
  Mu_HS57           100                 HS57                                         `GGGGTAAAATAGCCAATATTCCA`       `CCAACAAGCCATATTTGTTTTTC`         KT893428[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS12           201                 HS12                                         `GGAGGTAAAACGATATTCTCCTTAAA`    `TGAAGATTTTGAATGGATGTGTG`         KT868848[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS27           280                 HS27                                         `GAATAAATATTGCTTCCATACTTTCAA`   `GCAAAATGAGAATCTCCACCA`           KT893437[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS21           801                 HS21                                         `TGGATGGGATATTGATGACAA`         `CCCTGGAAGAGTATGGGACA`            KT868849[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS31           857                 HS5 & HS31                                   `GGCAAAGAGCTTTATTTTGTTGA`       `GCCGTAGCAACATCAAATACA`           KT868847[^h^](#t003fn008){ref-type="table-fn"}
  ***Mix Gamma***                                                                                                                                      
  Mu_HS44           148                 HS44                                         `AGAAGATGCACTAGGCTCTAG`         `GCTATCTAATTCCATCCCTG`            JF496678[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS45           128                 HS45, HS5, HS32 & HS60                       `TCCACTTGGGATGAAAAGGA`          `ACCGCATACTTTGAGCCTGT`            KT893432[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS29           185                 HS29                                         `CCCATATTTAAACAATGGAGTGA`       `TCATACTTTGAAAAACATTATCTGGA`      KT868846[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS22           216                 HS22                                         `TCATGGAGCTGGAACAACAG`          `GCTGGAACTTCTTTTGCAATC`           KT893439[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS9            278                 HS9                                          `AAAACTATTAGCTTGATTTTACCTTGG`   `GCGAAAGACGGATTGTTCAT`            KT868844[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS37           541                 HS37                                         `TGGATGAAGGGGACTTATGG`          `TGGTTTGAAGAGCATCAGCA`            KT893431[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS18           653                 HS18                                         `CAGCTATAAATCATGGGTATTGGA`      `GTAATCAATACATTTTTCCTTGCTT`       KT932997[^h^](#t003fn008){ref-type="table-fn"}
  lpxA              331                 *C*. *jejuni* sp.                            `ACAACTTGGTGACGATGTTGTA`        `CAATCATGDGCDATATGASAATAHGCCAT`   \[[@pone.0144349.ref044]\]
  ***Mix Delta***                                                                                                                                      
  Mu_HS58           85                  HS58 and HS32                                `TCCGGAAAAATTTTATTTAGATTCTC`    `AACAATACCAGGATACCAATCTTCA`       KT893427[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS52           170                 HS52                                         `AAAACACGCTATTAATCATGGTGAC`     `ATGTAGGCCAAGTTATACAACCTTTT`      KT893429[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS60           241                 HS60                                         `GAAATCATTTTTATGATATTGTGGTT`    `TCACAGTCACAATAAATAGCCAAA`        KT893426[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS55           341                 HS55                                         `GAGATGGTGGTGGTCATCAA`          `ACGTTGCAACCAATCCTTTG`            KT893433[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS32           420                 HS32                                         `GCATACCAGATGGCTTTGG`           `AATGCAGCGTGCTTCTTATTT`           KT893435[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS11           540                 HS11                                         `GAATTGGACATAACCACGGAAT`        `ATGCAAAGTGCACATATTCTCC`          KT868845[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS40           636                 HS40                                         `CAACCCTTGGATGACAATAGAGA`       `ACCGTCAATATCATCAGGATTTA`         KT893434[^h^](#t003fn008){ref-type="table-fn"}
  Mu_HS38           741                 HS38                                         `GCCGCAGGAGATAATGAAGA`          `TTTGCCTTTTAGATCTTGAGGA`          KT893430[^h^](#t003fn008){ref-type="table-fn"}

^*a*^ Genbank accession number of the DNA sequence used to design the primers

^*b*^ Parkhill et al., 2000 \[[@pone.0144349.ref010]\]

^*c*^ Poly et al., 2011 \[[@pone.0144349.ref032]\]

^*d*^ HS4A represent HS4, HS13, HS16, HS43, HS50, HS62, HS64 and HS65

^*e*^ Pearson et al., 2007 \[[@pone.0144349.ref019]\]

^*f*^ Karlyshev et al., 2005 \[[@pone.0144349.ref031]\]

^*g*^ Fouts et al., 2005 \[[@pone.0144349.ref015]\]

^*h*^ this study

^*i*^ HS4B includes CG8486, HS16 & HS64

^*j*^ Poly et al., 2007 \[[@pone.0144349.ref014]\]

![Illustration of PCR amplicons expected when using the updated *C*. *jejuni* CPS multiplex PCR.\
Lane 1, 100-bp NEB DNA standard; lane 2, mixture of PCR products obtained with all the templates from the alpha mix; lane 3, 100-bp NEB DNA standard; lane 4, mixture of PCR products obtained with all the templates from the beta mix; lane 5, 100-bp NEB DNA standard; lane 6, mixture of PCR products with all the templates from the gamma mix; lane 7, 100-bp NEB DNA standard; lane 8, mixture of PCR products with all the templates from the gamma mix.](pone.0144349.g003){#pone.0144349.g003}

Interpretation of results {#sec012}
-------------------------

As shown in [Table 4](#pone.0144349.t004){ref-type="table"}, some primer sets can show extraneous bands, but the system has been designed to facilitate discrimination. For example, the HS5 template should yield an 857 bp product in mix beta, but it also yields a 129 bp product with the HS45 primer set found in mix gamma. Therefore, if an unknown template yields only a 129 bp product in mix gamma, the CPS type is HS45, but if it yields both a 129 bp product in mix gamma and an 857 bp product in mix beta, the strain is an HS5. Similarly, as described previously \[[@pone.0144349.ref032]\], HS31 DNA templates should produce a 857 bp product in mix beta, but they also produce a 325 bp product with the HS15 primer set found in mix alpha. The designed HS45 and HS15 primers do not match any sequences of HS5 and HS31 genomes respectively when compared by BLAST algorithm. The reason for these amplifications is still unclear. Nevertheless these additional bands do not interfere with the attribution of HS5 and HS31 CPS types.

10.1371/journal.pone.0144349.t004

###### Summary of the *C*. *jejuni* capsule multiplex PCR expected results.

![](pone.0144349.t004){#pone.0144349.t004g}

  Capsule type           Mix Alpha                                              Mix Beta                                              Mix Gamma                                              Mix Delta
  ---------------------- ------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------
  HS1                    \-                                                     Mu_HS1 (610bp)                                        \-                                                     \-
  HS2                    Mu_HS2 (62bp)                                          \-                                                    \-                                                     \-
  HS3                    Mu_HS3 (149bp)                                         \-                                                    \-                                                     \-
  HS4 (HS4 complex)      Mu_HS4A (370bp)                                        \-                                                    \-                                                     \-
  CG8486 (HS4 complex)   \-                                                     Mu_HS4B (652bp)                                       \-                                                     \-
  HS5 (HS5 complex)      \-                                                     Mu_HS5 (857bp)                                        Mu_HS45 (129bp)[\*](#t004fn001){ref-type="table-fn"}   \-
  HS6 (HS6 complex)      Mu_HS6 (185bp)                                         \-                                                    \-                                                     \-
  HS7 (HS6 complex)      Mu_HS6 (185bp)                                         \-                                                    \-                                                     \-
  HS8 (HS8 complex)      \-                                                     Mu_HS8 (342bp)                                        \-                                                     \-
  HS9                    \-                                                     \-                                                    Mu_HS9 (278bp)                                         \-
  HS10                   Mu_HS10 (229bp)                                        \-                                                    \-                                                     
  HS11                   \-                                                     \-                                                    \-                                                     Mu_HS11 (540bp)
  HS12                   \-                                                     Mu_HS12 (200bp)                                       \-                                                     \-
  HS13 (HS4 complex)     Mu_HS4A (370bp)                                        \-                                                    \-                                                     \-
  HS15                   Mu_HS15 (325bp)                                        \-                                                    \-                                                     \-
  HS16 (HS4 complex)     Mu_HS4A (370bp)                                        Mu_HS4B (652bp)                                       \-                                                     Mu_HS52 (170bp)[\*](#t004fn001){ref-type="table-fn"}
  HS17 (HS8 complex)     \-                                                     Mu_HS8 (342bp)                                        \-                                                     \-
  HS18                   \-                                                     \-                                                    Mu_HS18 (653bp)                                        \-
  HS19                   Mu_HS19 (450bp)                                        \-                                                    \-                                                     \-
  HS21                   \-                                                     Mu_HS21 (800bp)                                       \-                                                     \-
  HS22                   \-                                                     \-                                                    Mu_HS22 (216bp)                                        \-
  HS23 (HS23 complex)    \-                                                     Mu_HS23 (161bp)                                       \-                                                     \-
  HS27                   \-                                                     Mu_HS27 (280bp)                                       \-                                                     \-
  HS29                   \-                                                     \-                                                    Mu_HS29 (185bp)                                        \-
  HS31 (HS5 complex)     Mu_HS15 (325bp)[\*](#t004fn001){ref-type="table-fn"}   Mu_HS5 (857bp)                                        \-                                                     \-
  HS32                   \-                                                     Mu_HS8 (342bp)[\*](#t004fn001){ref-type="table-fn"}   Mu_HS45 (129bp)[\*](#t004fn001){ref-type="table-fn"}   Mu_HS32 (420bp)
  HS33 (HS33 complex)    Mu_HS33 (819bp)                                        \-                                                    \-                                                     \-
  HS35 (HS33 complex)    Mu_HS33 (819bp)                                        \-                                                    \-                                                     \-
  HS36 (HS23 complex)    \-                                                     Mu_HS23 (161bp)                                       \-                                                     
  HS37                   \-                                                     \-                                                    Mu_HS37 (541bp)                                        
  HS38                   \-                                                     \-                                                    \-                                                     Mu_HS38 (740bp)
  HS40                   \-                                                     \-                                                    \-                                                     Mu_HS40 (636bp)
  HS41                   Mu_HS41 (279bp)                                        \-                                                    \-                                                     \-
  HS42                   \-                                                     Mu_HS42 (440bp)                                       \-                                                     \-
  HS43 (HS4 complex)     Mu_HS4A (370bp)                                        \-                                                    \-                                                     \-
  HS44                   \-                                                     \-                                                    Mu_HS44 (148bp)                                        \-
  HS45                   \-                                                     \-                                                    Mu_HS45 (129bp)                                        \-
  HS50 (HS4 complex)     Mu_HS4A (370bp)                                        \-                                                    \-                                                     \-
  HS52                   \-                                                     \-                                                    \-                                                     Mu_HS52 (170bp)
  HS53                   Mu_HS53 (251bp)                                        \-                                                    \-                                                     \-
  HS55                   \-                                                     \-                                                    \-                                                     Mu_HS55 (355bp)
  HS57                   \-                                                     Mu_HS57 (100bp)                                       \-                                                     \-
  HS58                   Mu_HS15 (325bp)[\*](#t004fn001){ref-type="table-fn"}   \-                                                    \-                                                     Mu_HS58 (89bp)
  HS60                   \-                                                     \-                                                    Mu_HS45 (129bp)[\*](#t004fn001){ref-type="table-fn"}   Mu_HS60 (240bp)
  HS62 (HS4 complex)     Mu_HS4A (370bp)                                        \-                                                    \-                                                     \-
  HS63                   Mu_HS63 (520bp)                                        \-                                                    \-                                                     \-
  HS64 (HS4 complex)     Mu_HS4A (370bp)                                        Mu_HS4B (652bp)                                       \-                                                     \-
  HS65 (HS4 complex)     Mu_HS4A (370bp)                                        \-                                                    \-                                                     \-

(\*) un-expected amplification.

During validation, it was also observed that Mu_HS15 primers (325 bp), which were in the alpha mix in the original multiplex, also recognized the HS58 type strain DNA template found in mix delta (89 bp). This observation would suggest that the first generation multiplex was falsely recognizing HS58 strains as HS15. Nucleotide sequence comparisons confirmed a region of homology within the CPS loci of both HS15 and HS58. However, in the current multiplex, amplification of this product does not interfere with attribution of both HS15 or HS58 CPS types, and the Mu_HS15 original primer set was retained in the current multiplex PCR.

Similarly, the Mu_HS8 primers used in the original mix were found to amplify a sugar biosynthesis gene found in the HS32 Penner type strain ([Table 4](#pone.0144349.t004){ref-type="table"}). Thus, the Mu_HS8 primers generate a 342 bp amplicon from mix beta on both strains, but discrimination of HS32 is made by the presence of a 420 bp product (Mu_HS32) in mix delta. In addition, it was observed that HS32 type strain is also recognized by Mu_HS45 primers in mix gamma yielding a 129 bp amplicon. Again because these extraneous amplifications do not interfere with either CPS attribution, the original Mu_HS8 primers were retained in mix beta and Mu_HS32 primers were added to mix delta.

The CPS locus of the type strain of HS45 appeared to be a mosaic of multiple serotypes, an observation that complicated primer design (C. T Parker, unpublished). Primers were designed based on the HS45 sequence with the knowledge that they would also amplify HS5, HS32, and HS60 ([Table 4](#pone.0144349.t004){ref-type="table"}).

Primers for CPS types in related complexes {#sec013}
------------------------------------------

Many CPS types fall into related complexes, e. g. HS23 and HS36 ([Fig 1](#pone.0144349.g001){ref-type="fig"}). DNA sequencing of the CPS loci had previously revealed that the type strains of HS23 and HS36 share 97.6% DNA sequence identity and \>87.9% protein identity \[[@pone.0144349.ref031]\]. Both strains express the same repeating capsular trisaccharide, but the HS23 type strain was shown to lack the MeOPN modification and one of the four variable heptoses found in HS36 \[[@pone.0144349.ref031]\]. The primer Mu_HS23 developed in the first multiplex version was retained and does not distinguish HS23 and HS36 capsule types.

The HS4 complex is the largest complex and is composed of eight separate serotypes (HS4, HS13, HS16, HS43, HS50, HS62, HS64 and HS65) ([Fig 1](#pone.0144349.g001){ref-type="fig"}) \[[@pone.0144349.ref025]\]. Only the capsule structure of a clinical isolate from Thailand, CG8486, that typed as HS4/13/64 has been published \[[@pone.0144349.ref030]\]. The primer set named HS4 (alpha mix, 370bp) and CG8486 (beta Mix, 652bp) in the first publication \[[@pone.0144349.ref032]\] were re-named HS4A and HS4B, respectively. These primer sets were designed based on the MeOPN transferases present in each strain \[[@pone.0144349.ref014], [@pone.0144349.ref032]\]. Due to the high recombination rate of *C*. *jejuni* strains, isolates that would react with both HS4A and HS4B primers were anticipated and observed (see below). The CPS biosynthesis loci of all 8 type strains in the complex and of CG8486 are highly conserved (C. T Parker, unpublished). Primers HS4A react positively with all eight individual serotypes associated with the HS4 complex, but not with CG8486, as demonstrated in a previous study \[[@pone.0144349.ref032]\]. Primers HS4B positively recognize CG8486, HS16 and HS64 and this is consistent with the presence of the CG8486 MeOPN transferase-like gene in these three strains (C. T Parker, unpublished). These data suggest that differences among strains within the HS4 complex include differences in the position of MeOPN attachment, an observation that has been confirmed by determination of CPS structure (Monteiro et al, in preparation).

HS5 and HS31 belong to the same complex \[[@pone.0144349.ref025]\] and are indistinguishable based on their CPS loci gene content (C. T Parker, unpublished). Thus, both HS5 and HS31 are detected by the presence of an 857 bp amplicon in mix beta generated by the Mu_HS5 primers ([Table 4](#pone.0144349.t004){ref-type="table"}).

The CPS loci of the type strains from three additional Penner complexes, HS6/7, HS8/17, and HS33/35, also showed high conservation. The HS8/17 complex was discussed previously \[[@pone.0144349.ref032]\]. The Mu_HS6 was designed in the previous CPS multiplex PCR version. The HS6 capsule type remains obscure, due to the fact that CPS has been shown not to be the serodeterminant of the HS6 serotype and might explain the high number of false positive identified with Mu_HS6 designed previously \[[@pone.0144349.ref031], [@pone.0144349.ref032]\]. Nevertheless, sequencing of the HS7 Penner type strain showed that the entire HS7 biosynthesis locus was over 99% identical to that of the HS6 type strain (C. T Parker, unpublished). This result corroborates the frequent association of HS6 and HS7 in the Penner typing literature \[[@pone.0144349.ref027]\]. Finally, it appears that the CPS biosynthesis loci of the type strains of HS33 and HS35 are over 99% identical at the nucleotide level (C. T Parker, unpublished). The Mu_HS33 primer designed in this new version recognizes both serotypes.

The HS1 complex, which includes HS1 and HS44, can also be detected by the same primer set, producing a 610 bp amplicon in mix beta. Additional information on the HS1 complex will be presented separately (F. Poly, unpublished).

Collectively, the sequencing data suggests that strains within these complexes express similar/related CPS structures despite belonging to different serotypes.

Application of the multiplex to clinical isolates from Thailand {#sec014}
---------------------------------------------------------------

Nine hundred and ninety isolates were positive for the *C*. *jejuni* species-specific gene (*lpxA*) by gamma mix multiplex PCR and six isolates were negative. This result confirms the high level of correlation between the *lpxA* PCR and classic phenotypical methods for the characterization of *C*. *jejuni* sp. \[[@pone.0144349.ref044]\]. The CPS multiplex PCR assay identified 98% of all 990 *C*. *jejuni* isolates in this study. There were a total of 20 untypeable strains, 17 from Nepal (12 from indigenous population, 5 from travelers), and three from Cambodia, representing 12.8 and 12.5% of the isolates in each respective country ([Table 5](#pone.0144349.t005){ref-type="table"}). This higher of level of non-typeable isolates in those countries does not appear to be random or attributable to method failure. This may indicate presence of localized undefined/unreported capsule types that are not included in the current capsule typing method that was developed largely on strains from North America and Europe \[[@pone.0144349.ref045]\]. Validation of this hypothesis will require further analysis.

10.1371/journal.pone.0144349.t005

###### Capsule multiplex PCR results among all *C*. *jejuni* isolates from different population group from South and South-East Asia.

In bold are the five most prevalent CPS types in their respective group. Number in parentheses represent the number of strain in the category.

![](pone.0144349.t005){#pone.0144349.t005g}

                      Foreign population   Indigenous population                                                                      
  ------------------- -------------------- ----------------------- --------------- ---------------- --------------- ----------------- -----------------
  HS1/44 complex      2% (1)               4.9% (13)                               2.1% (2)         **8.3% (2)**    6.8% (35)         5.4% (53)
  HS2                 3.9% (2)             **8% (21)**             **17.4% (8)**   **7.4% (7)**     **29.2% (7)**   **19.7% (101)**   **14.7% (146)**
  HS3 complex         **13.7% (7)**        3.8% (10)               **10.9% (5)**   **7.4% (7)**     4.2% (1)        **9.2% (47)**     **7.8% (77)**
  HS4 complex         5.9% (3)             **22.8% (60)**          **8.7% (4)**    **7.4% (7)**     **12.5% (3)**   **15.8% (81)**    **16.1% (158)**
  HS5/31 complex      **15.7% (8)**        5.7% (15)               **8.7% (4)**    **8.5% (8)**     **12.5% (3)**   **13.1% (67)**    **10.6% (105)**
  HS6/7 complex                                                    **8.7% (4)**    **11.7% (11)**                   1.2% (6)          2.1% (21)
  HS8/17 complex      5.9% (3)             5.7% (15)               2.2% (1)        4.3% (4)         **8.3% (2)**    **14.1% (72)**    **9.8% (97)**
  HS9                 2% (1)                                       6.5% (3)        2.1% (2)                         2.7% (14)         2% (20)
  HS10                5.9% (3)             1.5% (4)                2.2% (1)        1.1% (1)         **8.3% (2)**    4.7% (24)         3.5% (35)
  HS11                3.9% (2)                                                     2.1% (2)                         0.2% (1)          0.5% (5)
  HS15                **11.8% (6)**        3.8% (10)               2.2% (1)        1.1% (1)                         0.4% (2)          2% (20)
  HS21                2% (1)                                                       6.4% (6)                         0.2% (1)          0.8% (8)
  HS22                                                             4.3% (2)        3.2% (3)                                           0.5% (5)
  HS23/36 complex     **7.8% (4)**         **16.7% (44)**                          2.1% (2)                         2.3% (12)         6.3% (62)
  HS37                5.9% (3)             3.8% (10)               2.2% (1)        1.1% (1)         4.2% (1)        3.1% (16)         3.2% (32)
  HS41                                                             6.5% (3)        2.1% (2)                                           0.5% (5)
  HS42                                     **6.1% (16)**           2.2% (1)        3.2% (3)                                           2% (20)
  HS53                **7.8% (4)**         **14.8% (39)**          2.2% (1)        1.1% (1)                         2.7% (14)         6% (59)
  HS57                                                                             3.2% (3)                                           0.3% (3)
  Other               6% (3)               2.4% (6)                4.4% (2)        9.6% (9)                         3.69% (19)        3.9% (39)
  Untypeable                                                       10.9% (5)       12.8% (12)       12.5% (3)                         2% (20)
  Not *C*. *jejuni*                                                                2.1% (2)         4.2% (1)        0.6% (3)          0.6% (6)
  Number of strains   51                   263                     46              96               25              515               996

Overall, as shown in [Table 5](#pone.0144349.t005){ref-type="table"}, the five most common CPS types observed from all sites were the HS4 complex (16.1%), HS2 (14.7%), HS5/31 complex (10.6%), HS8/17 complex (9.8%) and HS3 complex (7.8%). In 2013, Pike and colleagues published a longitudinal study of the most common Penner serotypes worldwide. One of the observations of the study is that HS4 complex, HS2 and HS1/44 complex were the most common serotypes in both developing and developed countries. Surprisingly, our survey demonstrates that HS1/44 type is less frequent in this population, but is still significantly represented with 5.4% of cases in the south and Southeast Asian regions ([Table 5](#pone.0144349.t005){ref-type="table"}).

Comparison of capsule distribution of total foreign versus indigenous population, shows some noticeable differences ([Fig 4](#pone.0144349.g004){ref-type="fig"}). Isolates from CPS types belonging to HS2 (8.7% vs 18.3%, p\<0.01), HS5/31 complex (7.5% vs 12.4%, p = 0.019) HS6/7 complex (1.1% vs 2.7%, p = 0.098), HS8/17 complex (5.3 vs 12.4%, p\<0.01), HS9 (1.1% vs 2.5%, p = 0.098), are underrepresented in foreign population, while HS15 (4.7% Vs 0.5%, p\<0.01), HS23/36 complex (13.3% Vs 2.2%, p\<0.01), HS42 (4.7% Vs 0.5%, p\<0.01) and HS53 (12.2% Vs 2.4%, p\<0.01) are over represented in isolates collected from foreign visitors. A closer look at the foreign population visiting Thailand, travelers and military population, highlight a dichotomy in those two groups ([Table 5](#pone.0144349.t005){ref-type="table"}): The five most common CPS types in non-military travelers to Thailand are the HS5/31 complex (15.7%), HS3 complex (13.7%), HS15 (11.8%) and the HS23/36 (7.8%) and HS53 (7.8%), whereas the five most common CPS types in military personnel deployed to Thailand were the HS4 complex (22.8%), the HS23/36 complex (16.7%), HS53 (14.8%), HS2 (8%), and HS42 (6.1%). The difference of CPS distribution between those two groups is not easy to explain. However, it is likely that isolates from these military exercises had higher clonal relationships than the other isolates studied. The annual military exercises in Thailand take place for one month or less at different locations, and off-duty military personnel may consume the same contaminated foods from local vendors. In addition while there is no differences of the top five most common CPS types between travelers and indigenous population in Nepal, there are noticeable differences between the travelers and indigenous population in Thailand ([Table 5](#pone.0144349.t005){ref-type="table"}). Capsule types HS2, HS4 and HS8/17 complexes are under-represented and HS15, HS53 and HS23/36 complex are over-represented in travelers to Thailand compared to the Thai population ([Table 5](#pone.0144349.t005){ref-type="table"}). While some of those differences can be explained by clonality/outbreaks, the differences are most likely multifactorial and include regional isolation for foreign visitors, differences in food consumed, and/or seasonal changes. Nonetheless, this is important information to take in account for the development of a capsule based vaccine against *C*. *jejuni*.

![Comparison of the capsule type distribution between indigenous Southeast/South Asia population and foreign population.\
(\*) statistically significant (p\<0.01). (\*\*) statistically significant (p\<0.05).](pone.0144349.g004){#pone.0144349.g004}

Finally, no major temporal difference of capsule types distribution was observed in these pediatric populations during 2004--2006 (n = 302) and 2008--2010 (n = 213) time period. *C*. *jejuni* HS2, HS4 complex, HS8/17 complex, HS3, and HS5/31 complex were found as the five most common capsule types, accounting for nearly 70% of isolates in each of these two time periods (data not show).

Conclusions {#sec015}
===========

The burden of disease caused by *C*. *jejuni* is undeniable. It represents a major health risk for pediatric population living in developing countries as well as travelers visiting those regions. The most promising vaccine approach to alleviate campylobacteriosis in those populations is a capsule conjugate vaccine. A monovalent vaccine targeting HS23/36 CPS type has shown 100% protection in a non-human primate model \[[@pone.0144349.ref033]\]. To be efficacious a final vaccine should be multivalent and include the most prevalent and most pathogenic *C*. *jejuni* CPS types. In order to gain more information on CPS distribution worldwide we developed a multiplex PCR based approach. In this study we demonstrated the possibility of specifically determining CPS/Penner type through design of specific PCR primer pairs. Typing methods for *C*. *jejuni* remains are limited despite the availability of numerous whole genomes sequences in the last decade. The Penner serotyping method is time and labor intensive, and it is now only performed in a handful of laboratories worldwide. One the major drawbacks in addition to the cost and complexity of the typing sera, is the phase variability of CPS expression \[[@pone.0144349.ref022]\]. In contrast, the multiplex does not require capsule expression for attribution of capsule type.

A recent systematic review of clinical isolates *C*. *jejuni* Penner typing since the 80's demonstrate that over 85% of the typed strains were from developed countries. This result demonstrated the lack of information on pediatric population from the developing countries and the necessity to gain more information on CPS type distribution in those region where a CPS conjugate vaccine is the most needed \[[@pone.0144349.ref027]\]. This method provides a mechanism to address this deficit.

Analysis on almost 1000 clinical isolates collected from 1998 to 2010 in South East Asian peninsula showed that 98% of the *C*. *jejuni* strains were typeable. Knowing the *C*. *jejuni* CPS loci plasticity, the *C*. *jejuni* non-typeable isolates may represent unknown capsules that were not described in the Penner serotype system. Although there are marked differences between the major capsule types reported in the developed world \[[@pone.0144349.ref027]\] and those reported here from Asia, a limited number of capsule types account for most of the disease. Thus, the 8 most common CPS types account for 76.7% CPS in that region. Thus, these results suggest that the valency required for an effective *C*. *jejuni* conjugate vaccine is similar to that seen in the first pneumococcal conjugate vaccines.

Taken together, these observations validate the development of a multiplex PCR technique. The application of capsule multiplex PCR assay demonstrates simplicity and sensitivity of the technique. All equipment required is standard in most molecular microbiology laboratories. The PCR multiplexing reduces the number of reactions to be performed per samples, and this method is not affected by phase variation of capsule expression. Our study demonstrates the usefulness of the assay in geographical epidemiology for *C*. *jejuni* diarrhea and in describing CPS serotype among clonally related *C*. *jejuni* isolates from spatial distribution and possible outbreak situations.
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